Abstract 3153: Tag Polymorphisms of Tumor Necrosis Factor-Induced Protein 3 Gene Are Associated with Left Ventricular Hypertrophy in Hypertension
Background Tumor necrosis factor induced protein 3 (TNFAIP3) is an inhibitor of nuclear factor-κB (NF-κB) signaling, which has been implicated in cardiomyocyte hypertrophy. Recent study show that TNFAIP3 protects against apoptosis, improves cardiac remodeling. We hypothesized that the variants of TNFAIP3 gene was associated with left ventricular hypertrophy (LVH) in hypertension patients.
Methods and Results To test our hypothesis, four tag single nucleotide polymorphisms (SNPs) representative of all the other SNPs were genotyped in 2120 hypertensive patients, including 947 with LVH and 1173 without LVH, as well as 815 healthy control subjects. We found that only the tag SNP (rs5029939) was associated with LVH, which conferred a protective factor for LVH, (adjusted odds ratio OR 0.58, 95% confidence interval CI 0.358 – 0.863, P = 0.035), including septal wall thickness (9.03±1.39 mm for G allele versus 10.1±1.66 mm for A allele of rs5029939, P<0.01), posterior wall thickness (9.77±1.78 mm versus 10.6±1.88mm, P<0.01), LV mass index (44.7±10.7 g/m2.7 versus 49.7±17.4 g/m2.7, P<0.01) and relative wall thickness (43.6±7.9 % versus 45.6±10.8 %, P<0.01). No association of the other three SNPs genotype with echocardiographic variables was identified in hypertensive patients and in controls (P>0.05). Haplotype analysis confirmed that haplotype ATCG was associated with LVH (OR 1.545, 95% CI 1.181–2.020, P = 0.001)
Conclusions Our findings indicate that the SNP (rs5029939) polymorphism in the TNFAIP3 gene may serve as a novel protective genetic marker for the development of LVH in patients with hypertension.